Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or…
Year: 2023
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or…
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of…
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of…
Sanara MedTech Inc. Announces First Quarter 2023 Results
FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort…
Sanara MedTech Inc. Announces First Quarter 2023 Results
FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort…
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
– Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND…
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
– Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND…
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers…
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers…
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
– Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023…
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
– Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023…
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
NightHawk Biosciences Provides Q1 2023 Business Update
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…
NightHawk Biosciences Provides Q1 2023 Business Update
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…